Tag:

PolyRemedy

Latest Headlines

PolyRemedy nabs $20M in Series C

June 8, 2011

PolyRemedy has closed a $20 million Series C financing led by Delphi Ventures. Current investors MedVenture Associates, Advanced Technology Ventures and Flybridge Capital Partners also participated.

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
HTA in Medtech - Free SymposiumSaturday, June 2, 2012 — ISPOR Washington
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe

MORE EVENTS

Press Releases

Featured Jobs

District Sales Manager
Vivus, Inc. -
Sr. Director/Executive Director of Operations, Inflammation and Immunology CRD Job
Celgene Corporation - Tokyo, Ja, US
Director, Public Relations Job
Celgene Corporation - Summit, NJ, US
Oncology Knowledge Lead
Merck - Boston, MA
Sr. Director, Statistics Job
Celgene Corporation - Summit, NJ, US

PolyRemedy

Latest Headlines

Latest Headlines

PolyRemedy nabs $20M in Series C

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

PolyRemedy

Latest Headlines

Latest Headlines

PolyRemedy nabs $20M in Series C

Related Tags

Join 31,000+ Insiders SIGN UP FOR OUR NEWSLETTER

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance